More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The stars are aligned for another strong year of performance for CDMOs. DCAT Value Chain Insights examines industry fundamentals and an outlook for pharma outsourcing in 2020. Strong fundamentals but some risks 2019 proved to be a stellar year...

The FDA approved 48 new molecular entities in 2019, below the 59 NME approvals in 2018, a recent record high, but still the third highest number of approvals since 1996, when 53 NMEs were approved. Which companies and drugs scored FDA...

What are the key market developments in the pharmaceutical industry to watch for in 2020? DCAT Value Chain Insights highlights products projected for high growth prospects, important R&D projects, and overall market growth. Products to watch...

To extract continuous value from R&D activities and ensure manufacturing quality, pharmaceutical companies are – or should be – embracing digital transformation. This business journey uses technology to turn fragmented systems into a harmonized...

What key trends or issues emerged in 2019 that are positioned to be on the industry’s radar in 2020? DCAT Value Chain Insights provides a Top 10 ranking. Top 10 Developments from 2019 for the Industry Radar in 2020 1. Drug-pricing reform in the...

What was the most noteworthy activity from CDMOs/CMOs in 2019? DCAT Value Chain Insights’ Top 10 ranking reveals the companies involved in the most significant mergers and acquisitions and expansions from 2019. CDMOs/CMOs: A Top 10 Ranking of...

Bristol-Myers Squibb completed its $74-billion acquisition of Celgene last month to form a newly combined company with eight products of over $1 billion in annual sales and near-term revenue potential of over $15 billion in new launches. What was...

As 2019 comes to a close, what were the top news stories shaping the pharmaceutical industry? From mega acquisitions to deal-making in cell and gene therapies, to shifting supply lines from a still-to-be resolved Brexit and ongoing trade talks in...